Introduction
Heat shock protein 90 (Hsp90), is one of the most abundant proteins in the cell, reaching an expression level of 2-5% of total protein. It is evolutionarily conserved, ubiquitously expressed and plays an essential role in cell signaling, proliferation, and survival 1-11 as part of the proteostasis protein folding management system 8, 9, [12] [13] [14] . Hsp90 is an ATP-dependent molecular chaperone which, together with its regulatory co-chaperones and the Hsp70 chaperone/co-chaperone system, form the centerpiece of cellular proteostasis management of protein folding 8, 12, 15 . The Hsp90 chaperone and its multiple co-chaperones regulate the stability, trafficking, function and degradation of a wide range of client proteins and is therefore central to all cellular processes. Their specific roles in protein folding biology largely remains an enigma.
Moreover, the value of Hsp90 and its co-chaperones as therapeutic targets for management of proteostasis-dependent responses to familial and somatic genetic disease, and/or physical stress-related disease that impacts the function of the protein fold remains to be demonstrated in the clinic. Hsp90 plays a critical role in management of Spatial Covariance (SCV), a new biological principle based on Gaussian regression to describe central dogma and its role in dictating the biology of the protein fold in response to evolvability and natural selection 16 .
In humans, the genes that code for Hsp90 isoforms 5 include the mitochondrial tumor necrosis factor (TNF) receptor associated protein (TRAP1), the luminal endoplasmic reticulum localized, glucose regulated protein 94 (GRP94) (HSP90b), the stress inducible Hsp90a
(HSP90AA) and the constitutively expressed Hsp90b (HSP90AB) 5, 14 . The functional Hsp90 protein in cells exists as a homodimer, with each protomer composed of 4 domains: an Nterminal domain (NTD) containing the ATP-binding pocket, a charged linker connecting the NTD and the middle domain (MD), the MD, which is involved in client and co-chaperone binding as well as ATP hydrolysis and a C-terminal domain (CTD) involved in dimerization and recruitment of TPR containing co-chaperones via its MEEVD motif 5, 14 . The Hsp90 dimer undergoes a series of structural rearrangements during its ATP-binding and hydrolysis cycle. In the nucleotide-free (apo) form, the C-terminally dimerized Hsp90 adopts an open conformation, which closes upon ATP binding and hydrolysis, a process that promotes protein folding and is assisted by the action of its multiple co-chaperones 5, 14 , including the accelerator of Hsp90 ATPase (Aha1) [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] .
Aha1 is a two domain, Hsp90 co-chaperone conserved from yeast to man 21, 23, [33] [34] [35] . It competes with other Hsp90 co-chaperones for binding to Hsp90 and contributes to the functional activation of client proteins, including kinases, steroid hormone receptors and transcription factors 1, 4, 5, 33, 36, 37 , by stimulating the ATPase activity of Hsp90 [38] [39] [40] . We have previously shown that Aha1 binding to Hsp90 is asymmetric. It bridges the middle domain of one of the Hsp90 protomers in the Hsp90 dimer with the N-terminal domain of the other Hsp90 molecule to promote the N-terminal dimerization of Hsp90 and thereby stimulate its ATPase activity [38] [39] [40] . The silencing of Aha1 decreases client protein activation and increases cellular sensitivity to Hsp90 inhibitors 38, 41, 42 . In cystic fibrosis (CF), a reduction of the Aha1 expression levels in vivo corrects the trafficking and functional defect associated with the deletion of Phe508 (F508del) variant of the cystic fibrosis transmembrane conductance regulator (CFTR), the most abundant CF-associated mutation 32 . These data suggest an important role for reduced ATPase activity in the stabilization of mutant CFTR, a hypothesis that we posited can be extended to other Hsp90-associated diseases including cancer and neurodegenerative diseases 32, 38, 42 .
Numerous small molecule Hsp90 inhibitors have been developed and tested in clinical trials for cancer which exhibit an "addiction" to Hsp90
18, [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] . Many of these compounds, including the natural products geldanamycin (GA) and radicicol and their derivatives [54] [55] [56] [57] , target the NTD of Hsp90, blocking its ATPase activity by competing for the ATP binding pocket. To date, none of these compounds have met with clinical success in cancer indications [58] [59] [60] [61] [62] , an 6 effect that is likely due to the mechanism of action of these compounds, which are likely to completely inhibit the general activity of the essential Hsp90 protein responsible for maintaining proteostasis balance 8 To identify novel compounds that alter the ability of Aha1 to modulate the ATPase activity of Hsp90, we employed a high throughput screening (HTS) which monitors the ATPase activity of Hsp90 activity in the presence of Aha1. Using this Aha1-stimulated Hsp90 (ASH) assay we identified SEW04784 (SEW), a novel scaffold that disrupts ASH activity without inhibiting the basal Hsp90 ATPase activity. Using NMR, we show that SEW binds to the Cterminal domain of Aha1 to disrupt its asymmetric binding to Hsp90 leading to abrogation of the chaperoning activity of Hsp90 in vitro. In vivo, SEW exhibits therapeutic potential by blocking the transcriptional activity of prostate cancer (PCa) associated variants of the androgen receptor (AR) in a cell-based model of PCa. Additionally, SEW exhibits the ability to specifically clear toxic, phosphorylated tau species associated with tauopathies, such as Alzheimer's disease.
SEW is predicted to have high value in the clinic given the client-dependent role of Aha1 in mitigation of human protein misfolding diseases without directly impacting the basal ATPase function of the abundant and ubiquitous Hsp90.
Results

Small molecule inhibitors of Aha1-stimulated Hsp90 (ASH) ATPase activity
To identify small molecules that can inhibit ASH activity, we adapted an assay that is based on the ability of colored products to quench the inherent fluorescence of white microtiter plates 70, 71 . In brief, inorganic phosphate (Pi), originating from the Hsp90-mediated hydrolysis of ATP, can be complexed with molybdate to form phosphomolybdate. The latter can then bind to the quinaldine red (QR) dye to form a colored product that quenches the inherent fluorescence of the white microtiter plates ( Figure 1A) . In our study, compounds that inhibit the ATPase activity of Hsp90 will lead to a lower production of Pi and exhibit less fluorescence quenching.
We optimized this assay to monitor the ASH activity in 384-well plate format. Purified
Hsp90b and Aha1 were premixed and allowed to reach a binding equilibrium at room temperature. The test compounds were subsequently added and allowed to bind to their target proteins before the addition of ATP and transfer to 37°C to initiate the reaction. After the 3 h incubation, the QR reagent was added and the fluorescence of the white microtiter plates measured. The optimization of the assay revealed a Z' factor of 0.7, suggesting that the assay was suitable for high throughput screening efforts. We performed our screen using the 16,000
compound Maybridge library, which yielded 131 compounds exhibiting a percent inhibition of the ASH activity exceeding 3 standard deviations of the DMSO treated Hsp90+Aha1 control ( Figure   1B ). A secondary screen to validate these hit compounds reduced this number to 35 target compounds, with our lead compound, SEW04784 (SEW) (Figure 1C) , being the most potent that did not inhibit the basal Hsp90 ATPase activity (see below). An analog with undetectable activity in the ASH ATPase assay (SEW04777) was used as a reference control ( Figure 1D ).
Characterization of SEW04784
To characterize SEW, we first performed a titration of the compound to assess its potency in inhibiting the ASH activity. The titration revealed that SEW can completely inhibit this activity at a dose of 5 µM (Figure 2A ) and exhibits an IC50 of 0.3 µM (Figure 2B ), a value similar to that of the well characterized Hsp90 inhibitor, geldanamycin (GA), which exhibits an IC50 value of 0.14 µM ( Figure 2B ). In addition, we observed that while SEW is able to block the ASH (Figure 2A-C) , it did not affect the basal Hsp90 ATPase activity seen in the absence of Aha1 (Figure 2A, C) . These data suggest that SEW is a first-in-class compound exhibiting potent inhibitory effect on the co-chaperone stimulated ATPase activity without exerting an inhibitory action on basal Hsp90-allowing the chaperone to function normally in the absence of Aha1-dependent events.
To corroborate the Aha1-mediated ATPase inhibitory activity of SEW, we addressed the impact of this small molecule on the binding of Hsp90 and Aha1. To monitor the impact of Hsp90 binding on Aha1, we first labeled Aha1 with the molecular probe, acrylodan, whose fluorescence is sensitive to the local environment of labeled cysteine (Cys) residues. In Figure   2D , the fluorescence of acrylodan-labeled full length Aha1 (ac-Aha1) increases with increasing concentration of Hsp90 ( Figure 2D ). The addition of SEW to this binding event, significantly reduces the observed increase in ac-Aha1 fluorescence and causes a 50% increase in the KD value (1.7 ± 0.2 µM) for the Hsp90-Aha1 binding reaction relative to that seen in the presence of DMSO (1.1 ± 0.1 µM) ( Figure 2D ). These data suggest that SEW is disrupting the binding of Hsp90 to its regulatory co-chaperone Aha1, consistent with the ability of SEW to block the ASH activity.
In order to assess the specificity of SEW for inhibiting the ATPase activity of Hsp90, we monitored its ability to block ATP hydrolysis of Hsp70, a highly abundant cellular chaperone required for the delivery of client proteins to Hsp90
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, both alone and in the presence of its ATPase activating co-chaperone Hsp40, as well as in a multi-protein chaperone complex consisting of Hsp70, Hsp40, Hsp90, Hop, Aha1 and p23 (referred to as 6P). The data indicate that SEW does not block the basal ATPase activity of Hsp70 nor did it impact the Hsp40-stimulated ATPase activity of Hsp70 or the ATPase activity of the 6P complex (or multiple combinations thereof (not shown)), where the total ATP hydrolysis is dominated by Hsp70
( Figure 2E ). These data suggest that SEW is not acting as a general inhibitor of the major core chaperone, Hsp70, responsible for protein folding in the cell.
SEW04784 binds to the C-terminal domain of Aha1
Since we observed inhibition of the Aha1 dependent Hsp90 ATPase activity in the presence of SEW, we determined if this compound bound directly to Hsp90. We monitored the NMR. The addition of SEW to full-length Aha1 caused shifts in spectra number of cross peaks in the spectrum, indicating that the compound binds to Aha1 in a localized site ( Figure 3A) . Given that Aha1 is a 2-domain protein that is thought operate as a highly-flexible linked dimer 34, 38 , the location of the binding site was further assessed by examining the TROSY-HSQC spectra of the isolated N-terminal (NTD (1-163)) and C-terminal domains (CTD (164-338)) of Aha1 in the presence and absence of SEW. Addition of SEW does not cause any changes in the spectrum of the isolated NTD of Aha1 ( Figure 3B ), but significant chemical shift changes are observed in the CTD of Aha1 ( Figure 3C ). These changes map to the Hsp90 binding interface of the CTD of Aha1 ( Figure 3D ).
In order to confirm that SEW binds to the CTD of Aha1, we monitored the impact of its binding on the fluorescence of acrylodan labeled Aha1. We observed a dose-dependent fluorescence quenching of the acrylodan labeled full length Aha1 ( Figure 4A ) with a Kd of 1.74
µM. We also observed a dose-dependent quenching of the acrylodan fluorescence of Ac-CTD- with GA reduces the folding capacity to 75% of the control lacking GA. We observed that SEW causes similar reduction in the refolding capacity of the 6P system, suggesting that management of Hsp90 sensitive refolding of Fluc is dependent on the SEW sensitive activity of Aha1.
In order to capture the impact of SEW in vivo, we assessed its impact on cells stably expressing variants of the FLuc. In addition to the WT-FLuc, we studied 2 variants, L5-FLuc (R188Q) and L33-FLuc (R188Q/R261Q), that contain mutations that disrupt polar contacts in the 3-dimensional (3D) structure of the protein, thereby affecting their stability 74 . SEW caused a dose-dependent decrease in WT-FLuc activity above a dose of 5 µM ( Figure 5C ). This effect was more pronounced for the folding sensitive L33-FLuc variant, where we again observed a dose-dependent destabilization of the protein at a dose as low as 0.5 µM ( Figure 5C ). The L5 variant was also sensitive to SEW at a dose of 0.5 µM but retained significantly more activity than that seen with the L33 variant at increasing doses ( Figure 5C ). This SEW-dependent loss of folding of FLuc variants was not due to cytotoxicity since we did not observe any toxicity at the doses tested using the CellTiter Glo assay ( Figure 5D ). While the expression of the mutant FLuc variants cause a 25% reduction in cell viability relative to that seen in cells expressing the WT-FLuc, the addition of SEW to these cells did not further promote cytotoxicity ( Figure 5D ).
Therefore, it appears that SEW is capable of inhibiting the chaperoning activity of Hsp90 in the complex environment of the cell.
SEW04784 inhibits the activity of steroid hormone receptors (SHR)
In order to determine the impact of SEW on biologically relevant Hsp90 client proteins, we turned our attention to the steroid hormone receptor family (SHR). We assessed the ability of SEW to inhibit the transcriptional activity of two SHRs, namely the glucocorticoid receptor Figure 6D ) at a dose of 20 µM, suggesting that it could provide significant therapeutic benefit in the treatment of both androgen-dependent and castration resistant PCa (CRPC).
SEW04784 can reduce the expression of phospho-tau
Tau is a microtubule associated protein (MAP) that promotes and stabilizes the formation of axonal microtubules 82, 83 . Mutations or hyperphosphorylation of tau (p-tau) leads to altered microtubule binding culminating in the loss of axonal transport 84, 85 and tau aggregation 86 .
This latter effect is a hallmark of a series of neurodegenerative diseases termed tauopathies, the most prominent of which is Alzheimer's disease (AD), where p-tau aggregates can be found in neurofibrillary tangles, senile plaques and cellular processes [87] [88] [89] [90] [91] . p-tau aggregates have been shown to be sensitive to the protective action of the heat shock protein molecular chaperone system 91 . Recent evidence has demonstrated that small molecules inhibitors of both Hsp70 and Hsp90, or modulation of the expression of regulatory co-chaperones, can mediate the clearance of p-tau in cells [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] .
In order to address the ability of SEW to specifically target toxic p-tau species, we utilized a HeLa cell line stably expressing WT-tau(4R0N). Here, we observed that SEW selectively cleared p-tau, specifically pS396/pS404, in a dose dependent manner, where a complete elimination of this toxic species could be observed at a dose of 30 µM ( Figure 7A ).
The analog of SEW that had undetectable activity in the ASH ATPase assay, SEW04777
( Figure 1D ), did not affect the levels of p-tau, suggesting that the observed effects of SEW are To confirm the observation that SEW is promoting the preferential clearance of p-tau species, we employed the Phos-tag PAGE approach 98, 99 , which allows the separation of phosphoproteins on acrylamide based the degree of phosphorylation. To provide secondary validation in another physiologically relevant model, we tested the effect of SEW on p-tau levels from cultured brain slices from a 4 month old transgenic mouse (rTg4510), which expresses the P301L variant of tau, a mutation shown to disrupt microtubule binding 84, 101 and thereby increases the aggregation propensity of tau. We observed a dosedependent reduction in the levels of p-tau (pS396/S404) in mouse brain tissue ( Figure 7F ),
suggesting that SEW can provide protection to these toxic tau species.
Discussion
Herein, we describe the discovery and characterization of a novel inhibitor of the Aha1- 
Regulation of SHR function
The chaperoning activity of Hsp90 was first characterized using the well characterized , thus providing a way for these transformed cells to escape growth arrests mediated by AR inhibitory therapies.
Therefore, identifying therapeutic targets that are critical for the functionality of SHR and developing small molecules that can inhibit these growth promoting factors or their associated signaling pathways are of high importance as shown herein for Aha1 inhibitor scaffold SEW that inhibits both AR and GR activity in vivo by its interaction with Aha1.
While DLBD-AR variants have been shown to be refractory to Hsp90 inhibition 111, 112 , due to the fact that the Hsp90 binds to the AR via the LBD, we demonstrated that SEW is also able to inhibit both the constitutive and DHT-mediated expression of PSA in 22Rv1 cells that express both a WT-AR allele and the CRPC-associated AR-V7 DLBD variant, suggesting that an Hsp90-independent activity of Aha1, which is also sensitive to SEW04784, might contribute to the mechanism of inhibition of this subclass of PCa-associated AR variants. In addition, recent evidence suggests that the Hsp40-Hsp70 cycle is intimately involved in management of AR and a chalcone scaffold series that blocks AR function in promoting proliferation of numerous prostate cancer models operate through the Hsp70 co-chaperone Hsp40
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. These results illustrate the importance of the entire Hsp70-Hsp90 chaperone/co-chaperone cycle in client delivery and management of misfolding as drivers of prostate cancer progression.
Role of Aha1 in tauopathy
Hsp90 is critical for the biogenesis and functional cycling of numerous clients proteins in addition to SHR (https://www.picard.ch/Hsp90Int/index.php) 5, 113, 114 , with microtubule associated protein, tau, being one of the best characterized [87] [88] [89] [90] [91] 115 . Small molecule inhibitors of Hsp90 have emerged as potential therapeutic options for the treatment of tauopathies 87, 89, 90, 116 . While elimination of toxic aggregates has been demonstrated at the bench, translation to the bedside has been disappointing, largely due to the expected associated cytotoxicity given the central role of Hsp90 in proteostasis.
To Inhibiting Aha1 directly has the benefit of not altering the basal chaperoning function of Hsp90, thereby mitigating the cytotoxic issues seen with complete Hsp90 inhibition 58, 59 . Thus, a novel, specific and potent Aha1 inhibitor presents a potential therapeutic opportunity for the treatment of neurodegenerative diseases upon further SAR of the parent SEW scaffold (B. Tait and J.E.
Gestwicki, not shown).
While the cellular function of Aha1 is often exclusively considered in the context of its cochaperoning activity as an ATPase stimulating co-factor for Hsp90, the majority of Aha1 exists in an Hsp90-free state in human cells . Expression and purification of human Hsp70, Hsp40, Hop, Bag and p23. Hsp70 was purified as described with minor modifications 118 . Bag1 was purified as described with minor modifications 119 . HOP was purified as described with minor modifications 120 . p23 was purified as described with minor modifications 121 .
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Materials and Methods
Expression
Quinaldine Red Assay. Based on pioneering efforts of Gestwicki 71,122
, we developed a modified quinaldine red (QR) based HTS assay for screening of compounds that specifically inhibit Aha1. Quinaldine red (QR) reagent was made by mixing 1 g ammonium molybdate, dissolved in 14 ml of 4N HCl,,43 mg QR dye dissolved in 40 ml of 1N HCl and solutions, 1.2ml of 1% poly vinyl alcohol (PVA) and completing the volume to 100 ml with ddH20 water. To initiate the QR assay, 2.3 µM Hsp90 and 14 µM Aha1 were added to the wells of a 384-well white microtiter plate (Greiner Bio-one) in reaction buffer (25 mM Hepes pH 7.5, 10 mM MgCl2, and 1 mM DTT). The plate was subsequently centrifuged 250xg for 1 min and the proteins allowed to incubate at room temperature for 30 min. Subsequently, 50 nl of the test compounds from the Maybridge library (or DMSO vehicle) were pinned into the appropriate wells, the plate centrifuged at 250xg for 1 min and incubated at room temperature for 30 min. Samples were dialyzed into NMR buffer (50 mM sodium phosphate buffer pH 7.00, 150 mM NaCl, 5 mM MgCl2, 2% glycerol, 2 mM DTT, 0.05% sodium azide). 
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